US-based Emergent BioSolutions has completed proof-of concept manufacturing of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ).
The MVA Ebola Zaire vaccine candidate is expected to be used in a Phase I clinical trial being supported by a grant from the Wellcome Trust and the UK Department for International Development.
{iframe}http://drugdelivery.pharmaceutical-business-review.com/news/emergent-completes-proof-of-concept-production-of-new-ebola-vaccine-170315-4533797{/iframe}